新型钙通道阻滞剂尼伐地平可减轻大鼠的缺血性脑损伤。

Nilvadipine, a new calcium channel blocker, reduces ischemic brain injury in rats.

作者信息

Takakura S, Susumu T, Satoh H, Mori J, Shiino A, Handa J

机构信息

Department of Pharmacology, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.

出版信息

Jpn J Pharmacol. 1991 Aug;56(4):547-50. doi: 10.1254/jjp.56.547.

DOI:10.1254/jjp.56.547

PMID:1744995

Abstract

The effects of nilvadipine, a dihydropyridine type calcium channel blocker, on cerebral infarction induced by focal brain ischemia was studied in rats. The area of infarction was measured 24 hr after occlusion of the middle cerebral artery (MCA) in spontaneously hypertensive rats using triphenyltetrazolium chloride. Nilvadipine, given immediately after MCA occlusion, reduced the area of infarction significantly at doses of 0.32 mg/kg (i.p.) and 3.2, 10 and 32 mg/kg (p.o.). Nicardipine suppressed the area of infarction at a dose of 32 mg/kg (p.o.). The results suggest that nilvadipine is effective against ischemic brain injury.

摘要

研究了二氢吡啶类钙通道阻滞剂尼伐地平对大鼠局灶性脑缺血诱导的脑梗死的影响。使用氯化三苯基四氮唑在自发性高血压大鼠大脑中动脉（MCA）闭塞24小时后测量梗死面积。MCA闭塞后立即给予尼伐地平，剂量为0.32mg/kg（腹腔注射）和3.2、10和32mg/kg（口服）时，可显著减少梗死面积。硝苯地平在剂量为32mg/kg（口服）时可抑制梗死面积。结果表明，尼伐地平对缺血性脑损伤有效。